N Wilcken
Overview
Explore the profile of N Wilcken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, et al.
Ann Oncol
. 2006 Jul;
18(2):215-25.
PMID: 16831851
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
12.
Boyages J, Taylor R, Chua B, Ung O, Bilous M, Salisbury E, et al.
Br J Surg
. 2006 Apr;
93(5):564-71.
PMID: 16607692
Background: This study compared the application of the St Gallen 2001 classification with a risk index developed at the New South Wales Breast Cancer Institute (BCI Index) for women with...
13.
Duric V, Stockler M, Heritier S, Boyle F, Beith J, Sullivan A, et al.
Ann Oncol
. 2005 Aug;
16(11):1786-94.
PMID: 16126738
Background: Studies of women who had adjuvant chemotherapy for early breast cancer 10-20 years ago showed that many judged small benefits sufficient to make it worthwhile. Indications, regimens and supportive...
14.
Ghersi D, Wilcken N, Simes R
Br J Cancer
. 2005 Jul;
93(3):293-301.
PMID: 16052223
We compared the results of randomised trials comparing taxane-containing chemotherapy regimens with regimens not containing a taxane in women with metastatic breast cancer. The specialised register of the Cochrane Breast...
15.
Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J
Cochrane Database Syst Rev
. 2005 Apr;
(2):CD003372.
PMID: 15846660
Background: It is commonly thought that combining chemotherapy agents for treating women with metastatic breast cancer will result in regimens that are more active, offer superior tumour response rates with...
16.
Ghersi D, Wilcken N, Simes J, Donoghue E
Cochrane Database Syst Rev
. 2005 Apr;
(2):CD003366.
PMID: 15846659
Background: It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. Objectives: To identify and review the randomised evidence comparing...
17.
Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J
Cochrane Database Syst Rev
. 2004 Oct;
(4):CD003367.
PMID: 15495049
Background: Antitumour antibiotics are used in the management of metastatic breast cancer. Some of these agents have demonstrated higher tumour response rates than non-antitumour antibiotic regimens, however a survival benefit...
18.
Carrick S, Ghersi D, Wilcken N, Simes J
Cochrane Database Syst Rev
. 2004 Jul;
(3):CD003374.
PMID: 15266482
Background: Studies have reported high tumour response rates for platinum-containing regimens in the treatment of women with metastatic breast cancer. Objectives: To identify and review the evidence from randomised trials...
19.
Carrick S, Ghersi D, Wilcken N, Simes J
Cochrane Database Syst Rev
. 2004 Apr;
(2):CD003374.
PMID: 15106201
Background: Studies have reported high tumour response rates for platinum-containing regimens in the treatment of women with metastatic breast cancer. Objectives: To identify and review the evidence from randomised trials...
20.
Ghersi D, Wilcken N, Simes J, Donoghue E
Cochrane Database Syst Rev
. 2003 Aug;
(3):CD003366.
PMID: 12917963
Background: It is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. Objectives: To identify and review the randomised evidence comparing...